No Prescription |
 |
 | ||
|
TIBOFEM Generic Tibolone |
|
| ||
No Prescription » Prescription Drugs 16 » TIBOFEM Generic Tibolone Tibolone which is a synthetic steroid medicine used for hormone replacement therapy (HRT). It mimics the activity of the female sex hormones oestrogen and progesterone and the androgen testosterone in the body.Oestrogen is the main sex hormone in the female body. Certain parts of the body such as the vagina bones and breasts rely on oestrogens to function normally. When the levels of oestrogen are low these tissues can slowly degenerate as is experienced during and following the menopause. In addition low levels of oestrogen can cause distressing symptoms such as hot flushes night sweats mood swings or depressed mood reduced sex drive and vaginal dryness. Oestrogen levels decrease naturally during the menopause but also decrease following a hysterectomy (surgical menopause) and in women taking medicines called gonadorelin analogues eg leuprorelin for endometriosis.When taken by mouth tibolone is broken down into three compounds that act in a similar way to the natural oestrogen progesterone and testosterone found in the body. This helps restore the balance of hormones in the body and reduces the symptoms of menopause whether natural or otherwise.Tibolone is also sometimes used to prevent osteoporosis in postmenopausal women. The declining level of oestrogen at menopause can affect the bones causing them to become thinner and more prone to breaking. Tibolone's oestrogenic effect can help prevent bone loss and fractures that may occur in women in the years after menopause. However it is only used as a second-line option for women at high risk of fractures who cannot take other medicines that are licensed for preventing osteoporosis. Women considered to be at high risk of developing fractures following the menopause include those who have had an early menopause those with a family history of osteoporosis those who have had recent prolonged corticosteroid therapy (eg prednisolone) those with a small thin frame and smokers. Women experiencing a natural menopause should not start treatment with this medicine until twelve months after their last natural menstrual bleed. This is because the medicine may cause irregular menstrual bleeding if it is started sooner than this.Women who have had a surgical menopause or are taking gonadorelin analogues can start treatment immediately.What is it used for?Relieving the symptoms of oestrogen deficiency (eg hot flushes decreased sex drive depression) in women who have gone through the menopause.Prevention of osteoporosis in women who have gone through the menopause and are at high risk of fractures but cannot take other medicines used to prevent osteoporosis. Buy TIBOFEM Generic Tibolone and other Prescription Drugs 16 products online at Medstore. Buy Online at Medstore - Click Here!
About TIBOFEM Generic Tibolone: Product Type: Prescription Drugs 16 TIBOFEM ( Generic Tibolone ) TIBOFEM (Generic Tibolone) Generic Tibolone 2.5mg Generic Tibolone TIBOFEM
View more Prescription Drugs 16 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
